OTHER INFORMATION.
−Removed: During the three months ended March 31, 2024, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “nonRule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
+Added: During the six months ended June 30, 2024, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “nonRule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
The exhibits filed or furnished as part of this Quarterly Report on Form 10-Q are set forth on the Exhibit Index, which Exhibit Index is incorporated herein by reference.
4 unchanged sentences
(Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)
+Added: August 13, 2024
EXHIBIT INDEX
Exhibit Title
+Added: Amendment No.2 to Amended and Restated At Market Issuance Agreement dated May 2, 2024 between Theriva Biologics, Inc.
+Added: and A.G.P./Alliance Global Partners (incorporated by reference to Exhibit 10.3 to the Registrant’s Current Report on Form 8-K filed May 2, 2024, File No.
Certificate of Incorporation, as amended (Incorporated by reference to (i) Exhibit 3.1 of the Registrant’s Current Report on Form 8-K filed October 16, 2008, File No.
29 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.